Human papillomavirus and cervical cancer behavioral surveillance in the US

Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9066, USA.
Cancer (Impact Factor: 4.89). 11/2008; 113(10 Suppl):3013-30. DOI: 10.1002/cncr.23760
Source: PubMed


In the US, federal and state behavioral surveillance systems routinely monitor self-reported sexual behavior and Papanicolaou (Pap) test use to identify high-risk populations, trends, and disparities and to guide and evaluate interventions for cervical cancer prevention and control. Clinical uptake of human papillomavirus (HPV) vaccination and testing necessitates the expansion of behavioral surveillance systems. Cervical disease is the main focus of HPV-related behavioral surveillance because of greater cancer incidence and mortality relative to other susceptible organs, and the availability of effective technologies for prevention and control. In the current study, a framework is presented for the types of behaviors to monitor, their conceptual and operational definitions, target populations, and evidence supporting the reliability and validity of self-report measures. An overview is also provided of 8 population-based and 2 provider-based data systems that are nationally representative and accessible for behavioral surveillance research. Ongoing surveillance at the national, state, and local level is critical for monitoring the dissemination of HPV technologies and their impact on reducing disparities in the detection of precursor lesions, incidence of invasive cancer, and mortality.

Download full-text


Available from: Jasmin A Tiro, Nov 05, 2014
11 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Men who have sex with men (MSM) bear the greatest burden of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) in every state in the U.S., but their populations are poorly defined. We estimated and compared populations of MSM in 2007 by region, state, and race/ethnicity. We averaged findings from two statistical models we had previously developed to estimate the total state-specific percentage and number of males who were MSM. The models were based, respectively, on state-specific rural/ suburban/urban characteristics and an index using state-specific household census data on same-sex male unmarried partners. A third model, based on racial/ethnic ratios from a nationally representative behavioral survey, partitioned these statewide numbers by race/ethnicity. Of an estimated 7.1 million MSM residing in the U.S. in 2007, 71.4% (5.1 million) were white, 15.9% (1.1 million) were Hispanic, 8.9% (635,000) were black, 2.7% (191,000) were Asian, 0.4% (26,000) were American Indian/Alaska Native, 0.1% (6,000) were Native Hawaiian/other Pacific Islander, and 0.6% (41,000) were of multiple/unknown race/ethnicity. The overall U.S. percentage of males who were MSM (6.4%) varied from 3.3% in South Dakota to 13.2% in the District of Columbia, which we treated as a state. Estimated numbers of MSM ranged from 9,612 in Wyoming to 1,104,805 in California. Plausible estimates of MSM populations by state and race/ethnicity can inform and guide HIV/AIDS surveillance, allocation of resources, and advocacy. They can help in the planning, implementation, and evaluation of HIV prevention programs and other services. Using MSM numbers as denominators, estimates of population-based MSM HIV incidence, prevalence, and mortality rates could help clarify national and state-level epidemic dynamics. Until corroborated by other modeling and/or empirical research, these estimates should be used with caution.
    Public Health Reports 01/2011; 126(1):60-72. DOI:10.2307/41639324 · 1.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The recent US Food and Drug Administration licensure of a prophylactic vaccine against oncogenic human papillomavirus (HPV) types 16 and 18, the first of its kind, poses unique challenges in postmarketing vaccine surveillance, especially in measuring vaccine effectiveness against biologic endpoints of HPV infection. Historically, the national system of population-based cancer registries in the US has provided high-quality data on cancer incidence and mortality for the most important biologic endpoints, namely, anogenital cancers and some oral cavity/oropharyngeal cancers. There also has been some data collection on cancer precursors; however, this activity has been inconsistent and of lower priority. Because effectiveness against HPV-associated cancers will not be measurable for several decades, strengthening and possibly expanding the capacity of registries to collect precancer data, which are earlier manifestations of infection, must be considered. Collecting type-specific data on HPV-associated precancers and cancers. While keeping in mind the current limitations of registry operations, they discuss resources that may be needed to implement and sustain these types of activities.
    Cancer 11/2008; 113(10 Suppl):3047-57. DOI:10.1002/cncr.23755 · 4.89 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This supplement, known as the ABHACUS (Assessing the Burden of HPV-Associated Cancers in the United States) supplement, contains 22 articles. Together, these articles provide a comprehensive snapshot of data related to the occurrence and control of multiple cancers that have been associated with the human papillomavirus (HPV). These analyses highlight the burden of HPV associated cancers in the US population as a whole and among vulnerable population subgroups. We anticipate that these findings will be an important resource for enhancing existing strategies for the prevention and control of HPV associated cancers. HPV is estimated to be responsible for 5.2% of the cancers diagnosed worldwide.1 Virtually 100% of cervical cancers are causally associated with HPV, and there is increasing evidence of the role that HPV plays in other anogenital cancers and oropharyngeal cancers. With the recent approval and recommendation of an HPV vaccine that contains HPV–16 and HPV–18, interest in quantifying the spectrum and burden of cancers is heightened. The International Agency for Research on Cancer (IARC) has determined that there is sufficient evidence for the carcinogenicity of HPV–16 in the cervix, vulva, vagina, penis, anus, oral cavity, and oropharynx.2 The IARC has found sufficient evidence of the role HPV–18 plays in cervical cancer, with limited or no evidence in other sites. Together, cervical cancer combined with the other HPV-associated cancers potentially afflicts an additional 25,000 persons every year in the US. Worldwide and in the US, the excitement and concern surrounding the HPV vaccine has been profound. The excitement derives from the potential of the vaccine to reduce the burden of cervical cancer in countries that have no screening infrastructure as well as in countries such as the US, in which nearly 11,000 women each year are told they have invasive cervical cancer and 4000 die from this disease, despite the availability of screening. The HPV vaccine also has the potential to impact a significant proportion of other cancers for which there typically is no routine screening. Conversely, the concern is that vaccine recipients may not continue to undergo screening for cervical cancer. Yet another concern is that if vaccine uptake is lower in those groups at highest risk of developing cervical cancer, current racial/ethnic or geographic disparities could increase. We hope that the articles in this supplement will highlight the burden and disparities associated with these cancers before vaccine implementation. This supplement includes an in-depth analysis of cancer incidence and mortality data from population- based central cancer registries that house highquality data. Fourteen articles are based mainly on cancer occurrence, using incidence data from population- based central cancer registries that participate in the Centers for Disease Control and Prevention (CDC)’s National Program of Cancer Registries (NPCR) and/or the National Cancer Institute (NCI)’s Surveillance, Epidemiology, and End Results (SEER) program. The NPCR program, which was established through the Cancer Registries Amendment Act passed by the US Congress in 1992, began providing financial support and technical assistance to population- based central cancer registries in 1994. This program currently supports central registries in 45 states, the District of Columbia, and 3 US territories; these registries cover approximately 96% of the US population. The SEER program, which was established as a result of the National Cancer Act of 1971, currently supports 14 such registries and 3 supplemental registries, covering approximately 26% of the US population. The population-based central cancer registries collect information on all reportable cancer cases within a state or another defined geographic area. Today, the NPCR and SEER programs together cover 100% of the US population, and data regarding more than 1 million new invasive cancer cases are added each year. Medical records are the primary source of the data. Both the NPCR and SEER data are collected and reported with the use of uniform data items and codes, as documented by the North American Association of Central Cancer Registries.3 The Institute of Medicine has recognized the importance of these 2 programs as valuable resources for studies on cancer.4
    Cancer 11/2008; 113(10 Suppl):2837-40. DOI:10.1002/cncr.23753 · 4.89 Impact Factor
Show more